We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -7.67 | -4.58% | 159.6218 | 167.46 | 157.65 | 167.26 | 10,721,784 | 01:00:00 |
From Apr 2019 to Apr 2024
By Michael Dabaie
AbbVie Inc. (ABBV) said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for Rinvoq for the treatment of adult patients with moderate to severe active rheumatoid arthritis.
The CHMP positive opinion is supported by data from the pivotal Phase 3 SELECT rheumatoid arthritis program evaluating more than 4,400 patients, AbbVie said. The opinion will now be referred to the European Commission for final approval, the company said.
In Phase 3 trials, upadacitinib improved signs and symptoms of rheumatoid arthritis, inhibited radiographic progression and improved physical function, AbbVie said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
October 18, 2019 08:07 ET (12:07 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
